CountryFocus: Healthcare Regulatory and Reimbursement Landscape-The Netherlands

Region:Europe

Author(s):

Product Code:GDHC0069CHR

Download Sample Report download
Buy the Full ReportStarting from $1995
Published on

December 2017

Total pages

175

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $1995

About the Report

About the Report

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-The Netherlands

Summary

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-The Netherlands". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in the Netherlands. It identifies the key trends in the country'shealthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData'steam of industry experts.

The value of the pharmaceuticals market decreased from USD 7.1 billion in 2009 to USD 5.3 billion in 2016 at a negative Compound Annual Growth Rate (CAGR) of 4%, and this value is expected to decrease further from USD 5.1 billion in 2017 to USD 4.3 billion in 2021 at a negative CAGR of 4%. The medical device market was worth USD 3.5 billion in 2016 and is projected to reach USD 4.3 billion by 2021 at a CAGR of 4%.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the Netherlands, and includes

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

Profiles and SWOT analyses of the major players in the pharmaceutical market: Teva, Pfizer, Merck, Roche, and AbbVie; and of major players in the medical device market: Medtronic, Essilor, Roche, Zimmer Biomet, and Ethicon

An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country'shealthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices

Detailed analysis of the country'shealthcare environment, demographics, healthcare infrastructure and healthcare expenditure

An overview of the opportunities for and challenges to growth in the Netherlands' healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to

Develop business strategies by understanding the trends shaping and driving the Netherlands' healthcare market

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact the Netherlands' healthcare market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors' performance

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Products

Table of Contents

Table of Contents

1 Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

3 Introduction

3.1 GlobalData Report Guidance

4 Overview of Pharmaceutical and Medical Device Markets

4.1 Pharmaceutical Market

4.1.1 Market Overview

4.1.2 Pharmaceutical Imports and Exports

4.1.3 Supply Channels

4.1.4 Market Segments

4.1.5 Overview of Major Therapeutic Areas

4.1.6 Major Players

4.2 Medical Device Market

4.2.1 Market Overview

4.2.2 Overview of Top Five Segments

4.2.3 Major Players

4.3 Market Drivers and Barriers

4.3.1 Drivers

4.3.2 Barriers

5 Market Access

5.1 Overview of Healthcare system

5.2 Reimbursement and Payer Landscape 1

5.3 Reimbursement Process

5.3.1 Overview of Insurance Providers

5.3.2 Patient Share in Healthcare Expenditure

5.3.3 Price Trends in the Healthcare Sector

5.3.4 Pricing Policies

5.4 Regulatory Landscape

5.4.1 Overview of Regulatory Agencies

5.4.2 Market Authorization Procedure for Pharmaceutical Products

5.4.3 Market Authorization Procedure for Medical Devices

5.4.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing

5.4.5 Licensing Process for Pharmaceutical Exports and Imports

5.4.6 Intellectual Property Rights

5.4.7 Clinical Trial Regulations 13

5.4.8 Pharmaceutical Advertising Regulations 13

5.4.9 Pharmacy Regulations 13

5.4.10 Labeling and Packaging Regulations 13

6 Country Healthcare Landscape

6.1 Healthcare Policy Initiatives

6.2 Healthcare Infrastructure

6.2.1 Healthcare Facilities

6.2.2 Healthcare Parameters

6.2.3 Healthcare Personnel

6.2.4 Environmental Health 15

6.3 Healthcare Expenditure

6.3.1 Overview

6.3.2 Share of Public and Private Sectors

6.3.3 Major Components of Healthcare Expenditure

6.4 Trade Associations

6.4.1 Nefemed

6.4.2 Nefarma

6.4.3 Neprofarm

6.4.4 Diagned

6.5 Trade Fairs

7 Opportunities and Challenges

7.1 Opportunities

7.2 Challenges

8 Appendix

8.1 Abbreviations

8.2 Bibliography

8.3 Research Methodology

8.3.1 Coverage

8.3.2 Secondary Research

8.3.3 Forecasts

8.3.4 Expert Panel

8.4 Contact Us

8.5 Disclaimer


List of Figure

1.2 List of Figures

Figure 1: Pharmaceutical Market, Netherlands, Revenue (USD bn), 2009-2021

Figure 2: Medical Device Market, Netherlands, Revenue (USD bn), 2009-2021

Figure 3: Country Profile, Netherlands, 2017

Figure 4: Pharmaceutical Market, Netherlands, Revenue (USD bn), 2009-2016

Figure 5: Pharmaceutical Market, Netherlands, Revenue (USD bn), 2017-2021

Figure 6: Pharmaceutical Market, Netherlands, Imports and Exports (USD bn), 2009-2016

Figure 7: Pharmaceutical Market, Netherlands, Distribution Channels, 2016

Figure 8: Pharmaceutical Market, Netherlands, EU Countries, Generic Drugs Market Share (%), 2016

Figure 9: Pharmaceutical Market, Netherlands, OTC Drugs Market Sales (USD m), 2011-2016

Figure 10: Pharmaceutical Market, Netherlands, Major OTC Drug Class Market Share (%), 2016

Figure 11: Pharmaceutical Market, Netherlands, Expenditure on Major Medicine Groups (USD m), 2013

Figure 12: Medical Device Market, Netherlands, Revenue (USD bn), 2009-2016

Figure 13: Medical Device Market, Netherlands, Revenue (USD bn), 2017-2021

Figure 14: Medical Device Market, Netherlands, Revenue by Segment (USD m), 2016

Figure 15: Cardiovascular Device Market, Netherlands, Revenue (USD m), 2009-2016

Figure 16: Cardiovascular Device Market, Netherlands, Market Share of Major Players (%), 2016

Figure 17: Ophthalmic Device Market, Netherlands, Revenue (USD m), 2009-2016 6

Figure 18: Ophthalmic Device Market, Netherlands, Market Share of Major Players (%), 2015

Figure 19: In Vitro Diagnostic Market, Netherlands, Revenue (USD m), 2009-2017 6

Figure 20: In Vitro Diagnostic Market, Netherlands, Market Share of Major Players (%), 2017

Figure 21: Orthopedic Device Market, Netherlands, Revenue (USD m), 2009-2016

Figure 22: Orthopedic Device Market, Netherlands, Market Share of Major Players (%), 2016

Figure 23: Wound Care Management Market, Netherlands, Revenue (USD m), 2009-2017

Figure 24: Wound Care Management Market, Netherlands, Market Share of Major Players (%), 2017

Figure 25: Major Players, Netherlands, Revenue (USD m), 2016

Figure 26: Healthcare Market, Netherlands, Drivers and Barriers, 2017

Figure 27: Market Access, Netherlands, Organizational Structure of Healthcare System, 2016 1

Figure 28: Market Access, Netherlands, Drug Reimbursement Process, 2014

Figure 29: Market Access, Netherlands, Structure of Health Insurance, 2016

Figure 30: Healthcare Expenditure, Netherlands, Out-of-Pocket Expenditure (%), 2009-2016

Figure 31: Market Access, Netherlands, Consumer Price Index Annual Change (%), 2009-2015

Figure 32: Market Access, EU, Centralized Procedure, Market Authorization, Pre-submission Phase, 2017

Figure 33: Market Access, EU, Centralized Procedure, Market Authorization, Pre-opinion Phase, 2017

Figure 34: Market Access, EU, Centralized Procedure, Market Authorization, Post-opinion Phase, 2017

Figure 35: Market Access, EU, Decentralized Procedure, Market Authorization, 2017

Figure 36: Market Access, EU, Conformity Assessment of Class I Medical Devices, 2017

Figure 37: Market Access, EU, Conformity Assessment of Class IIa Medical Devices, 2017

Figure 38: Market Access, EU, Conformity Assessment of Class IIb Medical Devices, 2017

Figure 39: Market Access, EU, Conformity Assessment of Class III Medical Devices, 2017

Figure 40: Market Access, Netherlands, Patent Approval Process, 2016 13

Figure 41: Healthcare Infrastructure, Netherlands, Hospitals, 2009-2016

Figure 42: Healthcare Infrastructure, Netherlands, Diagnostic Units, 2009-2016

Figure 43: Healthcare Infrastructure, Netherlands, Hospitals Beds (per 1,000 population), 2009-2016

Figure 44: Demographics, Netherlands, Life Expectancy at Birth (years), 2009-2016

Figure 45: Demographics, Netherlands, Life Expectancy at Birth (years), 2017-2021 14

Figure 46: Demographics, Netherlands, Immunization Rate (%), 2009-2016

Figure 47: Demographics, Netherlands, Major Causes of Mortality (number of deaths), 2015

Figure 48: Demographics, Netherlands, Major Causes of Male Mortality (number of deaths), 2015

Figure 49: Demographics, Netherlands, Major Causes of Female Mortality (number of deaths), 2015

Figure 50: Demographics, Netherlands, Major Diseases, Disability-Adjusted Life Years by Major Disease (�000s), 2015

Figure 51: Healthcare Infrastructure, Netherlands, Doctors (per 1,000 population), 2009-2016

Figure 52: Healthcare Infrastructure, Netherlands, Nurses (per 1,000 population), 2009-2016

Figure 53: Healthcare Infrastructure, Netherlands, Dentists (per 1,000 population), 2009-2016

Figure 54: Healthcare Infrastructure, Netherlands, Pharmacists (per 1,000 population), 2009-2016

Figure 55: Healthcare Infrastructure, Netherlands, PM2.5 (�g per m�), 2009-2016 15

Figure 56: Healthcare Infrastructure, Netherlands, CO2 Emissions (kilotons), 2009-2016

Figure 57: Healthcare Expenditure, Netherlands, Healthcare Expenditure (% of GDP), 2009-2016

Figure 58: Healthcare Expenditure, Netherlands, Public-Private Share of Expenditure (%), 2009-2016

Figure 59: Healthcare Expenditure, Netherlands, Major Components of Healthcare Expenditure (%), 2016

Figure 60: Healthcare Market, Netherlands, Opportunities and Challenges, 2017


List of Table

1.1 List of Tables

Table 1: Pharmaceutical Market, Netherlands, Revenue (USD bn), 2009-2016

Table 2: Pharmaceutical Market, Netherlands, Revenue (USD bn), 2017-2021

Table 3: Pharmaceutical Market, Netherlands, Imports and Exports (USD bn), 2009-2016

Table 4: Pharmaceutical Market, Netherlands, EU Countries, Generic Drugs Market Share (Volume %), 2016

Table 5: Pharmaceutical Market, Netherlands, Biosimilars Approved and Marketed, 2012

Table 6: Pharmaceutical Market, Netherlands, OTC Drugs Market Sales (USD m), 2011-2016

Table 7: Pharmaceutical Market, Netherlands, Major OTC Drug Class Market Share (%) and Revenue (USD m), 2016

Table 8: Pharmaceutical Market, Netherlands, Expenditure on Major Medicine Groups (USD m) and Share (%), 2013

Table 9: Pharmaceutical Market, Teva, Late-Stage Pipeline, 2017

Table 10: Pharmaceutical Market, Pfizer, Global, Late-Stage Pipeline, 2017

Table 11: Pharmaceutical Market, Merck, Global, Major Products, 2017

Table 12: Pharmaceutical Market, Merck, Global, Late-Stage Pipeline, 2017

Table 13: Pharmaceutical Market, Roche, Global, Revenue (USD m) and Annual Growth (%) of Major Products, 2016

Table 14: Pharmaceutical Market, Roche, Global, Late-stage Pipeline, 2017

Table 15: Pharmaceutical Market, AbbVie, Europe, Late-Stage Pipeline, 2017

Table 16: Medical Device Market, Netherlands, Revenue (USD bn), 2009-2016

Table 17: Medical Device Market, Netherlands, Revenue (USD bn), 2017-2021

Table 18: Medical Device Market, Netherlands, Revenue (USD m) and Market Share (%) by Segment, 2016

Table 19: Cardiovascular Device Market, Netherlands, Revenue (USD m), 2009-2016

Table 20: Cardiovascular Device Market, Netherlands, Revenue (USD m) and Market Share (%) of Major Players, 2016

Table 21: Ophthalmic Device Market, Netherlands, Revenue (USD m), 2009-2016 6

Table 22: Ophthalmic Devices Market, Netherlands, Revenue (USD m) and Market Share (%) of Major Players, 2015

Table 23: In Vitro Diagnostic Market, Netherlands, Revenue (USD m), 2009-2017 6

Table 24: In Vitro Diagnostic Market, Netherlands, Revenue (USD m) and Market Share (%) of Major Players, 2017

Table 25: Orthopedic Device Market, Netherlands, Revenue (USD m), 2009-2016

Table 26: Orthopedic Device Market, Netherlands, Revenue (USD m) and Market Share (%) of Major Players, 2016

Table 27: Wound Care Management Market, Netherlands, Revenue (USD m), 2009-2017

Table 28: Wound Care Management Market, Netherlands, Revenue (USD m) and Market Share (%) of Major Players, 2017

Table 29: Major Players, Netherlands, Revenue (USD m), 2016

Table 30: Medical Device Market, Medtronic, Global, Major Products, 2017

Table 31: Medical Device Market, Essilor, Netherlands, Major Products, 2017

Table 32: Medical Device Market, Roche, Netherlands, Major Products, 2017

Table 33: Medical Device Market, Zimmer Biomet, Global, Major Products, 2017

Table 34: Medical Device Market, Ethicon, Major Products, 2017

Table 35: Healthcare Expenditure, Netherlands, Out-of-Pocket Expenditure (%), 2009-2016

Table 36: Market Access, Netherlands, Consumer Price Index Annual Change (%), 2009-2015

Table 37: Healthcare Infrastructure, Netherlands, Hospitals, 2009-2016

Table 38: Healthcare Infrastructure, Netherlands, Diagnostic Units, 2009-2016

Table 39: Healthcare Infrastructure, Netherlands, Hospitals Beds (per 1,000 population), 2009-2016

Table 40: Demographics, Netherlands, Life Expectancy at Birth (years), 2009-2016

Table 41: Demographics, Netherlands, Life Expectancy at Birth (years), 2017-2021 1

Table 42: Demographics, Netherlands, Immunization Rate (%), 2009-2016

Table 43: Demographics, Netherlands, Major Causes of Mortality (number of deaths), 2015

Table 44: Demographics, Netherlands, Major Causes of Male Mortality (number of deaths), 2015

Table 45: Demographics, Netherlands, Major Causes of Female Mortality (number of deaths), 2015

Table 46: Demographics, Netherlands, Disability-Adjusted Life Years by Major Disease (�000), 2015

Table 47: Healthcare Infrastructure, Netherlands, Doctors (per 1,000 population), 2009-2016

Table 48: Healthcare Infrastructure, Netherlands, Nurses (per 1,000 population), 2009-2016

Table 49: Healthcare Infrastructure, Netherlands, Dentists (per 1,000 population), 2009-2016

Table 50: Healthcare Infrastructure, Netherlands, Pharmacists (per 1,000 population), 2009-2016

Table 51: Healthcare Infrastructure, Netherlands, PM2.5 (�g per m�), 2009-2016 1

Table 52: Healthcare Infrastructure, Netherlands, CO2 Emissions (kilotons), 2009-2016

Table 53: Healthcare Expenditure, Netherlands, Healthcare Expenditure (% of GDP), 2009-2016

Table 54: Healthcare Expenditure, Netherlands, Public-Private Share of Expenditure (%), 2009-2016

Table 55: Healthcare Expenditure, Netherlands, Major Components of Healthcare Expenditure (%), 2016

Table 56: Healthcare Expenditure, Netherlands, Major Healthcare Trade Fairs, 2017

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022